ADMA Biologics ADMA Stock
ADMA Biologics Price Chart
ADMA Biologics ADMA Financial and Trading Overview
| ADMA Biologics stock price | 13.24 USD |
| Previous Close | 13.19 USD |
| Open | 13.23 USD |
| Bid | 6.44 USD x 200 |
| Ask | 11.52 USD x 200 |
| Day's Range | 13.04 - 13.52 USD |
| 52 Week Range | 7.21 - 20.46 USD |
| Volume | 3.09M USD |
| Avg. Volume | 3.1M USD |
| Market Cap | 2.94B USD |
| Beta (5Y Monthly) | 0.656 |
| PE Ratio (TTM) | 17.194805 |
| EPS (TTM) | 0.77 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18 USD |
ADMA Valuation Measures
| Enterprise Value | 3B USD |
| Trailing P/E | 17.194805 |
| Forward P/E | 15.21839 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 5.65797 |
| Price/Book (mrq) | 6.727642 |
| Enterprise Value/Revenue | 5.787 |
| Enterprise Value/EBITDA | 12.482 |
Trading Information
ADMA Biologics Stock Price History
| Beta (5Y Monthly) | 0.656 |
| 52-Week Change | -15.98% |
| S&P500 52-Week Change | 13.08% |
| 52 Week High | 20.46 USD |
| 52 Week Low | 7.21 USD |
| 50-Day Moving Average | 10.42 USD |
| 200-Day Moving Average | 10.76 USD |
ADMA Share Statistics
| Avg. Volume (3 month) | 3.1M USD |
| Avg. Daily Volume (10-Days) | 5.54M USD |
| Shares Outstanding | 221.85M |
| Float | 217.57M |
| Short Ratio | 6.47 |
| % Held by Insiders | 1.96% |
| % Held by Institutions | 92.01% |
| Shares Short | 18.04M |
| Short % of Float | 10.04% |
| Short % of Shares Outstanding | 8.12% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | September 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 35.13% |
| Operating Margin (ttm) | 44.92% |
| Gross Margin | 68.52% |
| EBITDA Margin | 46.36% |
Management Effectiveness
| Return on Assets (ttm) | 22.40% |
| Return on Equity (ttm) | 41.94% |
Income Statement
| Revenue (ttm) | 519.15M USD |
| Revenue Per Share (ttm) | 2.24 USD |
| Quarterly Revenue Growth (yoy) | 5.09% |
| Gross Profit (ttm) | 355.76M USD |
| EBITDA | 240.7M USD |
| Net Income Avi to Common (ttm) | 182.41M USD |
| Diluted EPS (ttm) | 0.77 |
| Quarterly Earnings Growth (yoy) | 36.89% |
Balance Sheet
| Total Cash (mrq) | 124.56M USD |
| Total Cash Per Share (mrq) | 0.56 USD |
| Total Debt (mrq) | 202.8M USD |
| Total Debt/Equity (mrq) | 46.25 USD |
| Current Ratio (mrq) | 6.044 |
| Book Value Per Share (mrq) | 1.968 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 140.8M USD |
| Levered Free Cash Flow (ttm) | 90.26M USD |
Profile of ADMA Biologics
| Country | United States |
| State | NJ |
| City | Ramsey |
| Address | 465 State Route 17 |
| ZIP | 07446 |
| Phone | 201 478 5552 |
| Website | https://www.admabiologics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 640 |
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Q&A For ADMA Biologics Stock
What is a current ADMA stock price?
ADMA Biologics ADMA stock price today per share is 13.24 USD.
How to purchase ADMA Biologics stock?
You can buy ADMA shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ADMA Biologics?
The stock symbol or ticker of ADMA Biologics is ADMA.
Which industry does the ADMA Biologics company belong to?
The ADMA Biologics industry is Biotechnology.
How many shares does ADMA Biologics have in circulation?
The max supply of ADMA Biologics shares is 221.85M.
What is ADMA Biologics Price to Earnings Ratio (PE Ratio)?
ADMA Biologics PE Ratio is 17.19480500 now.
What was ADMA Biologics earnings per share over the trailing 12 months (TTM)?
ADMA Biologics EPS is 0.77 USD over the trailing 12 months.
Which sector does the ADMA Biologics company belong to?
The ADMA Biologics sector is Healthcare.
ADMA Biologics ADMA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
|
- | |||||
US Tech Composite
IXIC
US
|
25366.09 USD — |
-0.39
|
8.86B USD — | 25068.28 USD — | 25597.23 USD — | — - | 8.86B USD — |
|
US Tech Global Market Composite
NQGM
US
|
1958.3 USD — |
-2.44
|
— — | 1956.35 USD — | 1991.22 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7247.55 USD — |
-2.3
|
— — | 7246.35 USD — | 7373.62 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1372.96 USD — |
-1.99
|
— — | 1372.67 USD — | 1394.6 USD — | — - | — — |
|
US Tech Composite Total Return
XCMP
US
|
31344.11 USD — |
-0.38
|
— — | 30976.16 USD — | 31629.69 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
